Myelin does regenerate, but how well it regenerates depends heavily on where the damage occurs. In the peripheral nervous system, the nerves running through your arms, legs, and trunk, myelin repair is robust and reliable. In the brain and spinal cord, the process is slower, less efficient, and often incomplete, which is why conditions like multiple sclerosis cause lasting disability.
How Peripheral Nerves Rebuild Myelin
Peripheral nerves have a remarkable ability to remyelinate after injury. The cells responsible, called Schwann cells, do much of the heavy lifting. Each Schwann cell wraps a single segment of a single nerve fiber, maintaining a one-to-one relationship with that axon. When damage occurs, Schwann cells don’t just sit idle. They actively help clear away debris from the degenerated tissue, working alongside immune cells recruited from the bloodstream. Once the debris is removed, Schwann cells re-wrap the newly regenerating nerve fibers in fresh myelin.
Peripheral nerves regrow at roughly 1 millimeter per day in humans. That sounds small, but it adds up. A nerve injured near the elbow might take several months to reach the hand. A nerve damaged closer to the spine could take a year or more. The myelin coating follows along as the nerve extends, so recovery timelines for sensation and movement in a limb are largely set by this growth rate and the distance involved.
Why the Brain and Spinal Cord Struggle
The central nervous system uses a different cell type to produce myelin: oligodendrocytes. Unlike Schwann cells, a single oligodendrocyte can wrap segments of up to 50 different nerve fibers at once. When an oligodendrocyte is destroyed, all those segments lose their insulation simultaneously. Replacing that cell and restoring all of those connections is a far more complex task than the one-to-one repair that happens in peripheral nerves.
The brain and spinal cord do contain a reserve population of stem-like cells called oligodendrocyte progenitor cells (OPCs). These cells are scattered throughout the central nervous system and can, in theory, mature into new myelin-producing oligodendrocytes. When demyelination occurs, chemical signals released at the damage site attract OPCs to migrate in, make contact with the bare axon, and begin generating new myelin membrane that wraps and compacts around the nerve fiber. This process works reasonably well in young, healthy brains and in the early stages of diseases like MS. The problem is that it frequently stalls.
What Blocks Myelin Repair
In chronic MS lesions, the landscape around a damaged area becomes hostile to repair. Scar tissue formed by other brain cells (a process called gliosis) physically blocks OPCs from reaching bare axons. Leftover myelin debris that hasn’t been properly cleared sends inhibitory signals that prevent OPCs from maturing. Ongoing inflammation compounds the problem, and the axons themselves can sustain damage that makes them unable to accept new myelin even when OPCs are available.
The immune system plays a surprisingly nuanced role. Immune cells in the brain can shift between two functional states. In the early, pro-inflammatory state, these cells actually help by stimulating OPCs to multiply. But remyelination only progresses when the immune response transitions to an anti-inflammatory state. Cells in this second state secrete growth factors that push OPCs to mature into functioning oligodendrocytes. Research from the University of Edinburgh showed that when these anti-inflammatory immune cells were experimentally removed from lesions, oligodendrocyte maturation stalled and remyelination was significantly delayed. Efficient repair requires both phases, in the right sequence.
Aging Slows Remyelination Significantly
Like most regenerative processes in the body, myelin repair declines with age. Every step of remyelination gets slower as you get older, but the bottleneck is the final one: OPCs lose their ability to differentiate into mature, myelin-producing oligodendrocytes. Simply having more OPCs available doesn’t fix the problem. In aged animals, increasing OPC numbers at a damage site did not improve remyelination efficiency, confirming that the stall happens at the maturation step, not the recruitment step.
What’s particularly interesting is that this decline isn’t primarily caused by the OPCs themselves wearing out. Researchers at the University of Cambridge tested this by placing young OPCs onto tissue scaffolds made from aged brains, and old OPCs onto scaffolds from young brains. The OPCs behaved according to the age of the tissue they were sitting on, not their own age. Further investigation revealed that one key change in the aging brain is that it becomes physically stiffer. OPCs are mechanosensitive, meaning they respond to the stiffness of their surroundings. When placed on synthetic gels tuned to match the stiffness of a young brain, even old OPCs regained more youthful function. This finding suggests the repair machinery doesn’t break down so much as it gets stuck in an environment that no longer supports it.
That same research group found that calorie restriction through intermittent fasting, a well-established way to slow biological aging, improved remyelination in aged animals. Changes in nutrient-signaling pathways appear to be one mechanism connecting aging to OPC dysfunction.
Exercise and Myelin Health
Aerobic exercise appears to help maintain healthy myelination. In a study using a mouse model of Alzheimer’s disease, animals that did not exercise showed significant myelin deterioration in the brain by eight months of age, with loose and granulated myelin sheaths visible under electron microscopy. Mice that completed a six-month aerobic exercise program had less myelin damage, better-preserved populations of OPCs, and improved cognitive function compared to their sedentary counterparts. The exercise didn’t just slow decline; it appeared to stabilize both the myelin itself and the precursor cells responsible for maintaining it.
While this research was conducted in animals, it aligns with broader evidence that cardiovascular fitness supports brain health and white matter integrity in humans.
Drugs Designed to Promote Remyelination
For decades, MS treatments focused exclusively on reducing immune attacks on myelin, doing nothing to repair the damage already done. That’s beginning to change. The first proof that a drug could restore lost myelin in MS patients came from a trial of clemastine, an over-the-counter antihistamine. Researchers at UCSF discovered that clemastine worked by blocking a specific type of receptor on OPCs, which released them from a stalled state and prompted them to mature into oligodendrocytes. The drug was safe, but its effect was modest because it also hit several other receptors, diluting its impact.
A newer drug called PIPE-307 was engineered to target only the specific receptor responsible for the effect. In lab tests, PIPE-307 blocked that receptor far more potently than clemastine, drove OPCs to mature and begin myelinating nearby axons, and crossed the blood-brain barrier effectively. In a mouse model of MS, it reversed myelin degradation. PIPE-307 passed two Phase I safety trials in 2021 and is currently in Phase II trials in MS patients. No remyelination drug has yet received regulatory approval, but PIPE-307 represents the most targeted attempt so far to turn myelin repair into a treatable process rather than something left entirely to the body’s limited natural capacity.